Alnylam Pharmaceuticals Net Profit Margin Growth & History (ALNY)
Alnylam Pharmaceuticals's net profit margin was 8.45% for fiscal 2025.
View full Alnylam Pharmaceuticals company overviewAlnylam Pharmaceuticals annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 8.45% | +20.82 pp |
| 2024 | 2024-12-31 | −12.37% | +11.71 pp |
| 2023 | 2023-12-31 | −24.08% | +84.96 pp |
| 2022 | 2022-12-31 | −109.04% | −8.02 pp |
| 2021 | 2021-12-31 | −101.01% | +73.13 pp |
| 2020 | 2020-12-31 | −174.15% | +229.09 pp |
| 2019 | 2019-12-31 | −403.24% | +613.34 pp |
| 2018 | 2018-12-31 | −1,016.58% | −470.63 pp |
| 2017 | 2017-12-31 | −545.95% | +323.68 pp |
| 2016 | 2016-12-31 | −869.63% | — |
| 2010 | 2010-12-31 | −43.50% | +3.84 pp |
| 2009 | 2009-12-31 | −47.34% | −20.04 pp |
| 2008 | 2008-12-31 | −27.30% | — |
Alnylam Pharmaceuticals quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 12.74% | +22.08 pp |
| Q1 2026 | 2026-03-31 | 17.65% | +20.72 pp |
| Q4 2025 | 2025-12-31 | 13.96% | +28.08 pp |
| Q3 2025 | 2025-09-30 | 20.10% | +42.38 pp |
| Q2 2025 | 2025-06-30 | −9.34% | −6.78 pp |
| Q1 2025 | 2025-03-31 | −3.07% | +10.27 pp |
| Q4 2024 | 2024-12-31 | −14.12% | +17.23 pp |
| Q3 2024 | 2024-09-30 | −22.27% | −41.96 pp |
| Q2 2024 | 2024-06-30 | −2.56% | +84.04 pp |
| Q1 2024 | 2024-03-31 | −13.34% | +41.19 pp |
| Q4 2023 | 2023-12-31 | −31.35% | +30.58 pp |
| Q3 2023 | 2023-09-30 | 19.69% | +173.27 pp |
| Q2 2023 | 2023-06-30 | −86.59% | +36.79 pp |
| Q1 2023 | 2023-03-31 | −54.53% | +58.17 pp |
| Q4 2022 | 2022-12-31 | −61.93% | +38.04 pp |
| Q3 2022 | 2022-09-30 | −153.58% | −44.58 pp |
| Q2 2022 | 2022-06-30 | −123.39% | −37.44 pp |
| Q1 2022 | 2022-03-31 | −112.70% | +0.10 pp |
| Q4 2021 | 2021-12-31 | −99.97% | +48.93 pp |
| Q3 2021 | 2021-09-30 | −109.00% | +92.26 pp |
| Q2 2021 | 2021-06-30 | −85.95% | +86.45 pp |
| Q1 2021 | 2021-03-31 | −112.80% | +70.38 pp |
| Q4 2020 | 2020-12-31 | −148.90% | +236.40 pp |
| Q3 2020 | 2020-09-30 | −201.26% | +96.39 pp |
| Q2 2020 | 2020-06-30 | −172.40% | +318.46 pp |
| Q1 2020 | 2020-03-31 | −183.18% | +363.21 pp |
| Q4 2019 | 2019-12-31 | −385.30% | +619.98 pp |
| Q3 2019 | 2019-09-30 | −297.65% | +11557.45 pp |
| Q2 2019 | 2019-06-30 | −490.86% | +56.04 pp |
| Q1 2019 | 2019-03-31 | −546.39% | +98.45 pp |
| Q4 2018 | 2018-12-31 | −1,005.28% | −630.25 pp |
| Q3 2018 | 2018-09-30 | −11,855.10% | −11136.00 pp |
| Q2 2018 | 2018-06-30 | −546.90% | +196.39 pp |
| Q1 2018 | 2018-03-31 | −644.84% | −78.97 pp |
| Q4 2017 | 2017-12-31 | −375.03% | — |
| Q3 2017 | 2017-09-30 | −719.10% | — |
| Q2 2017 | 2017-06-30 | −743.28% | — |
| Q1 2017 | 2017-03-31 | −565.88% | — |
| Q1 2011 | 2011-03-31 | −77.93% | −27.76 pp |
| Q4 2010 | 2010-12-31 | −32.70% | — |
| Q3 2010 | 2010-09-30 | −34.81% | +3.17 pp |
| Q2 2010 | 2010-06-30 | −54.97% | +37.31 pp |
| Q1 2010 | 2010-03-31 | −50.17% | — |
| Q3 2009 | 2009-09-30 | −37.97% | — |
| Q2 2009 | 2009-06-30 | −92.28% | — |
Alnylam Pharmaceuticals net profit margin trends
Over the last five fiscal years, Alnylam Pharmaceuticals's net profit margin increased from −174.15% to 8.45%, a change of +182.59 percentage points. The latest reported quarter, Q2 2026, shows 12.74%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alnylam Pharmaceuticals source filings ↗